Health
Experimental intranasal influenza vaccine produces durable immune response – News-Medical.Net
An experimental single-dose, intranasal influenza vaccine was safe and produced a durable immune response when tested in a Phase 1 study published in the Journal…
An experimental single-dose, intranasal influenza vaccine was safe and produced a durable immune response when tested in a Phase 1 study published in the Journal of Clinical Investigation. The investigational vaccine, called Ad4-H5-VTN, is a recombinant, replicating adenovirus vaccine designed to spur antibodies to hemagglutinin, a protein found on the surface of influenza viruses that attaches to human cells.
The investigational vaccine was developed by Emergent Biosolutions Inc., (Gaithersburg,…
-
Business24 hours agoWhy is Alphabet stock worth less than Nvidia, Microsoft, Apple, and Amazon even though it is the most profitable S&P 500 company?
-
Noosa News23 hours ago‘Sunny, benign’ school holiday weather after morning showers in parts of Queensland
-
General18 hours agoDeveloper warns wind energy capacity may not be ready by WA coal deadline
-
General23 hours agoOlder Aussies back increased superannuation tax